RTA 402 Shown To Prevent Development Of Lung Cancer
16th Nov 2006, 18:21 GMT
Reata Pharmaceuticals, Inc. today announced the presentation of preclinical data showing that RTA 402 prevented the development of lung cancer in an established mouse model of the disease. This data, produced in the laboratory of Dr. [click link for full article]
Latest news from Health News from Medical News Today:
- Biotech Industry Welcomes WHO Initiative On Naming Of Biologicals Including Biosimilar Medicines
- Common Cause Of Heart Disease, Diabetes May Be Treatable With Malaria Drug
- Two Nerve Cells In Direct Contact
- Value Of 'Helper' Compound In Treating Some Leukemias
- Internists Take Home Several National Awards At AAMC Annual Meeting
- Most Canadian Med School Grads Lack Basic Surgical Skills
- ACP's Electronic Medical Resource Ranked No. 1 Evidence-based Tool By MLA's South Central Chapter
- University Of Illinois Scientist Helping Processors Keep E. Coli Out Of Meat
- American Thoracic Society Publishes New Statement On Hepatotoxicity Of Antituberculosis Therapy
- Neural Networking Nanotubes